Bacopa monnieri
Human research has examined specific Bacopa preparations and cognitive outcomes. Extract, standardization, amount, population and duration must match before evidence can inform a product assessment.
No FDA Daily Value, RDA, AI or UL
Trials commonly used defined extracts; those amounts are study context, not a daily requirement.
Compare nutrient-reference terminology →What the research can—and cannot—support
A systematic review of six 12-week trials found signals in some memory free-recall tests.
Other cognitive domains and populations were less consistently studied.
Very-low-certainty evidence does not establish Bacopa as treatment for Alzheimer disease.
Fields to verify on a real product
A familiar ingredient name is not enough to match a study or judge transparency.
Botanical identity and plant material
Powder versus extract
Extract ratio or bacoside standardization
Amount per serving and duration assumptions
Important reasons to pause
General information only. Suitability depends on the exact product, amount, health context and medication list.
- Digestive adverse effects are reported in some studies.
- Medication and medical-condition context should be reviewed.
- Do not use ingredient evidence to imply prevention or treatment of cognitive disease.
Where this ingredient appears in reviewed formulas
A label appearance does not transfer this ingredient evidence to the finished product. No affiliate link appears in this section.
Primary and evidence-synthesis sources
- Pase et al., 2012Systematic review of randomized trials in adults without significant cognitive impairment.
- McPhee et al., 2023Broader older-adult review with important risk-of-bias limitations.